Autologous hematopoietic stem cell transplantation for treatment of multiple myeloma patients with renal impairment
10.3760/cma.j.issn.1009-9921.2019.09.001
- VernacularTitle: 自体造血干细胞移植治疗伴肾功能不全的多发性骨髓瘤
- Author:
Wenrong HUANG
1
;
Daihong LIU
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China
- Publication Type:Review
- Keywords:
Multiple myeloma;
Renal insufficiency;
Hematopoietic stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2019;28(9):513-515
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a common hematological malignancy with renal impairment in approximately 50% of patients. Sever renal impairment occurs in 15%-20% of newly diagnosed multiple myeloma patients. 200 mg/m2 melphalan-based regimen (Mel 200 regimen) as conditioning regimen of autologous hematopoietic stem cell transplantation (AHCT) is suitable for multiple myeloma patients with mild or moderate renal impairment, and 400 mg/m2 melphalan-based regimen (Mel 140 regimen) is fit for multiple myeloma patients with severe renal impairment. As the first line therapy for multiple myeloma patients with renal impairment, AHCT can increase response depth, repair renal function and improve survival. AHCT is a safe and beneficial procedure for MM patients with renal failure.
